[Research progress on the differences between T and B cell responses to three different forms of human papilloma virus (HPV) vaccination]

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2024 Apr;40(4):378-382.
[Article in Chinese]

Abstract

One of the most prevalent malignancies in women is cervical cancer. Cervical cancer is mostly brought on by chronic high-risk human papillomavirus 16 (HPV16) and HPV18 infection. Currently, the widely used HPV vaccines are the bivalent Cervarix, the tetravalent Gardasil, and the 9-valent Gardasil-9.There are differences in T cell effector molecule changes, B cell antibody level, duration, age and the injection after vaccination of the three vaccines.

Publication types

  • Review
  • English Abstract

MeSH terms

  • B-Lymphocytes* / immunology
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / administration & dosage
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / immunology
  • Human Papillomavirus Viruses
  • Humans
  • Papillomavirus Infections / immunology
  • Papillomavirus Infections / prevention & control
  • Papillomavirus Infections / virology
  • Papillomavirus Vaccines* / administration & dosage
  • Papillomavirus Vaccines* / immunology
  • T-Lymphocytes* / immunology
  • Uterine Cervical Neoplasms / immunology
  • Uterine Cervical Neoplasms / prevention & control
  • Uterine Cervical Neoplasms / virology
  • Vaccination

Substances

  • Papillomavirus Vaccines
  • human papillomavirus vaccine, L1 type 16, 18
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18